Abstract CT401: NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival
Essam Ghazaly(Queen Mary University of London), Sarah P. Blagden(Churchill Hospital), Magdalena Ślusarczyk(Cardiff University), John G. Gribben(Queen Mary University of London), Christopher McGuigan(University College Dublin), Malcolm Mason(Velindre Cancer Centre)
Cited by 6
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
|Blood|2008|320